Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain

Brittany L. Forte, Lauren M. Slosky, Hong Zhang, Moriah R. Arnold, William D. Staatz, Meredith Hay, Tally M. Largent-Milnes, Todd W Vanderah

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Many cancerous solid tumors metastasize to the bone and induce pain (cancer-induced bone pain [CIBP]). Cancer-induced bone pain is often severe because of enhanced inflammation, rapid bone degradation, and disease progression. Opioids are prescribed to manage this pain, but they may enhance bone loss and increase tumor proliferation, further compromising patient quality of life. Angiotensin-(1-7) (Ang-(1-7)) binds and activates the Mas receptor (MasR). Angiotensin-(1-7)/MasR activation modulates inflammatory signaling after acute tissue insult, yet no studies have investigated whether Ang-(1-7)/MasR play a role in CIBP. We hypothesized that Ang-(1-7) inhibits CIBP by targeting MasR in a murine model of breast CIBP. 66.1 breast cancer cells were implanted into the femur of BALB/cAnNHsd mice as a model of CIBP. Spontaneous and evoked pain behaviors were assessed before and after acute and chronic administration of Ang-(1-7). Tissues were collected from animals for ex vivo analyses of MasR expression, tumor burden, and bone integrity. Cancer inoculation increased spontaneous pain behaviors by day 7 that were significantly reduced after a single injection of Ang-(1-7) and after sustained administration. Preadministration of A-779 a selective MasR antagonist prevented this reduction, whereas pretreatment with the AT 2 antagonist had no effect; an AT 1 antagonist enhanced the antinociceptive activity of Ang-(1-7) in CIBP. Repeated Ang-(1-7) administration did not significantly change tumor burden or bone remodeling. Data here suggest that Ang-(1-7)/MasR activation significantly attenuates CIBP, while lacking many side effects seen with opioids. Thus, Ang-(1-7) may be an alternative therapeutic strategy for the nearly 90% of patients with advanced-stage cancer who experience excruciating pain.

Original languageEnglish (US)
Pages (from-to)2709-2721
Number of pages13
JournalPain
Volume157
Issue number12
DOIs
StatePublished - Aug 10 2016

Fingerprint

Bone Neoplasms
Analgesics
Pain
Tumor Burden
Bone and Bones
angiotensin I (1-7)
Opioid Analgesics
7-Ala-angiotensin (1-7)
Neoplasms
Breast Neoplasms
Bone Remodeling
Bone Diseases
Femur
Disease Progression

Keywords

  • Angiotensin 1-7
  • Breast
  • Cancer
  • Chronic
  • MasR
  • Pain

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain. / Forte, Brittany L.; Slosky, Lauren M.; Zhang, Hong; Arnold, Moriah R.; Staatz, William D.; Hay, Meredith; Largent-Milnes, Tally M.; Vanderah, Todd W.

In: Pain, Vol. 157, No. 12, 10.08.2016, p. 2709-2721.

Research output: Contribution to journalArticle

Forte, BL, Slosky, LM, Zhang, H, Arnold, MR, Staatz, WD, Hay, M, Largent-Milnes, TM & Vanderah, TW 2016, 'Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain', Pain, vol. 157, no. 12, pp. 2709-2721. https://doi.org/10.1097/j.pain.0000000000000690
Forte, Brittany L. ; Slosky, Lauren M. ; Zhang, Hong ; Arnold, Moriah R. ; Staatz, William D. ; Hay, Meredith ; Largent-Milnes, Tally M. ; Vanderah, Todd W. / Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain. In: Pain. 2016 ; Vol. 157, No. 12. pp. 2709-2721.
@article{a6c5df3817aa4768aadb1d7240cb63c3,
title = "Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain",
abstract = "Many cancerous solid tumors metastasize to the bone and induce pain (cancer-induced bone pain [CIBP]). Cancer-induced bone pain is often severe because of enhanced inflammation, rapid bone degradation, and disease progression. Opioids are prescribed to manage this pain, but they may enhance bone loss and increase tumor proliferation, further compromising patient quality of life. Angiotensin-(1-7) (Ang-(1-7)) binds and activates the Mas receptor (MasR). Angiotensin-(1-7)/MasR activation modulates inflammatory signaling after acute tissue insult, yet no studies have investigated whether Ang-(1-7)/MasR play a role in CIBP. We hypothesized that Ang-(1-7) inhibits CIBP by targeting MasR in a murine model of breast CIBP. 66.1 breast cancer cells were implanted into the femur of BALB/cAnNHsd mice as a model of CIBP. Spontaneous and evoked pain behaviors were assessed before and after acute and chronic administration of Ang-(1-7). Tissues were collected from animals for ex vivo analyses of MasR expression, tumor burden, and bone integrity. Cancer inoculation increased spontaneous pain behaviors by day 7 that were significantly reduced after a single injection of Ang-(1-7) and after sustained administration. Preadministration of A-779 a selective MasR antagonist prevented this reduction, whereas pretreatment with the AT 2 antagonist had no effect; an AT 1 antagonist enhanced the antinociceptive activity of Ang-(1-7) in CIBP. Repeated Ang-(1-7) administration did not significantly change tumor burden or bone remodeling. Data here suggest that Ang-(1-7)/MasR activation significantly attenuates CIBP, while lacking many side effects seen with opioids. Thus, Ang-(1-7) may be an alternative therapeutic strategy for the nearly 90{\%} of patients with advanced-stage cancer who experience excruciating pain.",
keywords = "Angiotensin 1-7, Breast, Cancer, Chronic, MasR, Pain",
author = "Forte, {Brittany L.} and Slosky, {Lauren M.} and Hong Zhang and Arnold, {Moriah R.} and Staatz, {William D.} and Meredith Hay and Largent-Milnes, {Tally M.} and Vanderah, {Todd W}",
year = "2016",
month = "8",
day = "10",
doi = "10.1097/j.pain.0000000000000690",
language = "English (US)",
volume = "157",
pages = "2709--2721",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain

AU - Forte, Brittany L.

AU - Slosky, Lauren M.

AU - Zhang, Hong

AU - Arnold, Moriah R.

AU - Staatz, William D.

AU - Hay, Meredith

AU - Largent-Milnes, Tally M.

AU - Vanderah, Todd W

PY - 2016/8/10

Y1 - 2016/8/10

N2 - Many cancerous solid tumors metastasize to the bone and induce pain (cancer-induced bone pain [CIBP]). Cancer-induced bone pain is often severe because of enhanced inflammation, rapid bone degradation, and disease progression. Opioids are prescribed to manage this pain, but they may enhance bone loss and increase tumor proliferation, further compromising patient quality of life. Angiotensin-(1-7) (Ang-(1-7)) binds and activates the Mas receptor (MasR). Angiotensin-(1-7)/MasR activation modulates inflammatory signaling after acute tissue insult, yet no studies have investigated whether Ang-(1-7)/MasR play a role in CIBP. We hypothesized that Ang-(1-7) inhibits CIBP by targeting MasR in a murine model of breast CIBP. 66.1 breast cancer cells were implanted into the femur of BALB/cAnNHsd mice as a model of CIBP. Spontaneous and evoked pain behaviors were assessed before and after acute and chronic administration of Ang-(1-7). Tissues were collected from animals for ex vivo analyses of MasR expression, tumor burden, and bone integrity. Cancer inoculation increased spontaneous pain behaviors by day 7 that were significantly reduced after a single injection of Ang-(1-7) and after sustained administration. Preadministration of A-779 a selective MasR antagonist prevented this reduction, whereas pretreatment with the AT 2 antagonist had no effect; an AT 1 antagonist enhanced the antinociceptive activity of Ang-(1-7) in CIBP. Repeated Ang-(1-7) administration did not significantly change tumor burden or bone remodeling. Data here suggest that Ang-(1-7)/MasR activation significantly attenuates CIBP, while lacking many side effects seen with opioids. Thus, Ang-(1-7) may be an alternative therapeutic strategy for the nearly 90% of patients with advanced-stage cancer who experience excruciating pain.

AB - Many cancerous solid tumors metastasize to the bone and induce pain (cancer-induced bone pain [CIBP]). Cancer-induced bone pain is often severe because of enhanced inflammation, rapid bone degradation, and disease progression. Opioids are prescribed to manage this pain, but they may enhance bone loss and increase tumor proliferation, further compromising patient quality of life. Angiotensin-(1-7) (Ang-(1-7)) binds and activates the Mas receptor (MasR). Angiotensin-(1-7)/MasR activation modulates inflammatory signaling after acute tissue insult, yet no studies have investigated whether Ang-(1-7)/MasR play a role in CIBP. We hypothesized that Ang-(1-7) inhibits CIBP by targeting MasR in a murine model of breast CIBP. 66.1 breast cancer cells were implanted into the femur of BALB/cAnNHsd mice as a model of CIBP. Spontaneous and evoked pain behaviors were assessed before and after acute and chronic administration of Ang-(1-7). Tissues were collected from animals for ex vivo analyses of MasR expression, tumor burden, and bone integrity. Cancer inoculation increased spontaneous pain behaviors by day 7 that were significantly reduced after a single injection of Ang-(1-7) and after sustained administration. Preadministration of A-779 a selective MasR antagonist prevented this reduction, whereas pretreatment with the AT 2 antagonist had no effect; an AT 1 antagonist enhanced the antinociceptive activity of Ang-(1-7) in CIBP. Repeated Ang-(1-7) administration did not significantly change tumor burden or bone remodeling. Data here suggest that Ang-(1-7)/MasR activation significantly attenuates CIBP, while lacking many side effects seen with opioids. Thus, Ang-(1-7) may be an alternative therapeutic strategy for the nearly 90% of patients with advanced-stage cancer who experience excruciating pain.

KW - Angiotensin 1-7

KW - Breast

KW - Cancer

KW - Chronic

KW - MasR

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=84997771290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997771290&partnerID=8YFLogxK

U2 - 10.1097/j.pain.0000000000000690

DO - 10.1097/j.pain.0000000000000690

M3 - Article

VL - 157

SP - 2709

EP - 2721

JO - Pain

JF - Pain

SN - 0304-3959

IS - 12

ER -